Previous 10 | Next 10 |
Cytisinicline Up to Five Times More Likely to Result in Smoking Abstinence Compared to Placebo Phase 3 ORCA-2 Trial Currently Enrolling at 16 sites in United States SEATTLE, WA and VANCOUVER, BC / ACCESSWIRE / April 14, 2021 / Achieve Life Sciences, Inc. (NASDAQ:ACHV), a clinica...
Subjects treated with cytisinicline were 55% more likely to quit smoking at 6 months and experienced significantly fewer side effects compared to those who received varenicline SEATTLE, WA and VANCOUVER, BC / ACCESSWIRE / March 25, 2021 / Achieve Life Sciences, Inc. (NASDAQ:ACHV), a cl...
SEATTLE, WA and VANCOUVER, BC / ACCESSWIRE / March 15, 2021 / Achieve Life Sciences, Inc. (NASDAQ:ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, is pleased to announce the...
Achieve Life Sciences, Inc. (ACHV) Q4 2020 Earnings Conference Call March 11, 2021, 16:30 ET Company Participants Jaime Xinos - EVP, Commercial John Bencich - CEO & Director Jerry Wan - Senior Director, Accounting Operations & Principal Accounting Officer Cindy Jacobs - President &...
Achieve Life Sciences (ACHV): Q4 GAAP EPS of -$1.11 beats by $0.14.Cash and equivalents of $35.9M at December 31, 2020.Shares -1.7% AH.Press Release For further details see: Achieve Life Sciences EPS beats by $0.14
SEATTLE, WA and VANCOUVER, BC / ACCESSWIRE / March 11, 2021 / Achieve Life Sciences, Inc. (NASDAQ:ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced fourth qua...
SEATTLE, WA and VANCOUVER, BC / ACCESSWIRE / March 4, 2021 / Achieve Life Sciences, Inc. (NASDAQ:ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced that it w...
SEATTLE, WA and VANCOUVER, BC / ACCESSWIRE / February 24, 2021 / Achieve Life Sciences, Inc. (Nasdaq:ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, announced that three ...
SEATTLE, WA and VANCOUVER, BC / ACCESSWIRE / February 11, 2021 / Achieve Life Sciences, Inc. (NASDAQ:ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced ...
SEATTLE, WA and VANCOUVER, BC / ACCESSWIRE / January 7, 2021 / Achieve Life Sciences, Inc. (NASDAQ:ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation, today announced that John Bencich, Chief Execu...
News, Short Squeeze, Breakout and More Instantly...
Achieve Life Sciences Inc. Company Name:
ACHV Stock Symbol:
NASDAQ Market:
Achieve Life Sciences Inc. Website:
– Two New Independent Directors, Stuart Duty and Andrew Saik, Appointed – Third New Independent Director to Be Appointed to Board in Near Term MONTREAL and CHARLOTTE, N.C., July 15, 2024 (GLOBE NEWSWIRE) -- Milestone ® Pharmaceuticals Inc. (Nasdaq: MIST) (...
SEATTLE and VANCOUVER, British Columbia, July 09, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced that...
SEATTLE and VANCOUVER, British Columbia, July 01, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, announced that the c...